


Pierrel Group




Pierrel is a global player in the pharmaceutical indistry, with more than 70 years of experience in the oral care sector and listed on the Euronext Milan of Borsa Italiana.

The production plant received the first authorizations from the European Medicines Agency (EMA) in 1989 and that of the Food and Drug Administration (FDA) in 2009 for the aseptic production of drugs for injectable use.

Over the years, the core of our business has focused on the registration and marketing of dental anesthetics under the Pierrel brand; among them Orabloc, registered in the major international markets (including USA, Canada, Italy, Russia, Poland, Serbia, France, UK, Germany, Kosovo, Austria, Sudan, Taiwan and Indonesia).

Today, thanks to FDA approval, we have a significant market share in the USA and we have many registrations all over the world. Our specialization in the dental sector also extends to the research, development and distribution of medical devices



BOARD

GOVERNANCE

CORPORATE

S.P.A.

PIERREL

Raffaele Petrone CHAIRMAN
Rosario Bifulco VICE CHAIRMAN

Fulvio Citaredo CEO

Maria Paola Bifulco DIRECTOR
Fernanda Petrone DIRECTOR
Alessandra Piccinino DIRECTOR
Mauro Fierro DIRECTOR

AUDIT COMMITEE

Paolo Nagar CHAIRMAN Monica Valentino AUDITOR Fabio Rossi AUDITOR

Mena Menzione SUBSTITUTE AUDITOR Antonello Scimieri SUBSTITUTE AUDITOR

AUDIT COMPANY Pricewaterhause Coopers Spa

Development





A perfect mix between manufacturing experience and pharma know-how on registration, marketing and sale

Sale





	CONTRACT MANUFACTURING	PHARMA
Descripon	 Established in 2005, the Company leverages on excellent technical skills in drugs manufacturing High-quality dental cartridges manufacturer for top customers Manufacturing plant in Italy (20km from Naples) 	 Established in 2010, Pierrel Pharma registers and markets Pierrel and Orabloc branded dental anaesthecs , as well as develops innovative medical devices and drugs Pierrel Pharma is the Pierrel branded products' owner and exclusive distributor.
Key Services	 Complete contract manufacturing services with primary and secondary packaged material, analytical control and product release. 	 Markeng, sales, distribution. Development and registration of new molecules, drugs and medical devices for dental application. Clinical research and clinical trials.
Selected clients	Most important company in the dental industry	 Italian and international most important dealers

GLOBAL DENTAL ANAESTHETIC MARKET



Background of Industry

Local anesthetics are commonly used in dental practice. Today's availability of a variety of local anesthetic agents enables dentists to select an anesthec with specific properes, such as time of onset and duraon, hemostatic control, and degree of cardiac side effects.

The anesthetic agents available for dental use are: arcaine , lidocaine, mepivacaine, prilocaine and bupivacaine.

Arcaine is the market leader in Europe (East & West), Russia, CIS countries. Arcaine and lidocaine share the market equally in the USA. Lidocaine is the market leader in emerging markets.

The largest dental anesthetic market is North America (USA and Canada), valued at around 300m doses on a yearly basis.

In the USA the use of lidocaine exceeds that of arcaine because:

- 1) arcaine was introduced in the USA in 2000 (lidocaine in 1970)
- 2) arcai ne is more expensive than lidocaine (more than 50%)

It is estimated that the use of local anesthecs worldwide is more than 900m yearly doses and arcaine accounting for 35% of the total market

Worldwide consumption of dental anesthetic:


- About 1 bn cartridges per year amounting to around \$ 450m/year
- More than a quarter of which consumed in the USA accounting for \$150m/year
- Growth rate: 2%-3% per year

Market Players

- The main players in the dental anesthec market are the following:
 - Septodont (France)
 - Pierrel (Italy)
 - 3M Espe (Germany)
 - Sanofi Aventis (France)
 - Inibsa (Spain)
 - DFL (Brazil)

- Septodont, Pierrel and Inibsa are the only ones that rely on a global presence and are active with their brands and through private label agreements
- Pierrel accounts for 10% of the global market, in terms of producon capacity.
 Septodont accounts for 60% while the other players account for 30%

GLOBAL MARKET SHARE OF DENTAL ANESTHETICS



Source: Pierrel 27% 10





Warehouse

Labs

Produc on

Manufacuring Site authorized by AIFA, EMA, FDA

40,000 sqm available;11,000 sqm built of which6,000 sqm dedicated to the production





CONTACT:

Fulvio Citaredo CEO & Investor Relator f.citaredo@pierrelgroup.com

Francesco Pepe CFO f.pepe@pierrelgroup.com

PIERREL S.p.A. Capua (Ce) 81043 - ITALY Strada Statale Appia 7bis, 46/48 Tel. +39.0823.626.111 Fax. +39.0823.626.228